On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.

Autor: Pagan FL; Department of Neurology, Georgetown University Hospital, Washington DC, USA., Schulz PE; Department of Neurology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA., Torres-Yaghi Y; Department of Neurology, Georgetown University Hospital, Washington DC, USA., Pontone GM; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St., Phipps 300, Baltimore, MD, 21287, USA. gpontone@jhmi.edu.; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. gpontone@jhmi.edu.
Jazyk: angličtina
Zdroj: CNS drugs [CNS Drugs] 2024 May; Vol. 38 (5), pp. 333-347. Date of Electronic Publication: 2024 Apr 08.
DOI: 10.1007/s40263-024-01084-1
Abstrakt: Parkinson's disease (PD) is associated with the development of psychosis (PDP), including hallucinations and delusions, in more than half of the patient population. Optimal PD management must therefore involve considerations about both motor and non-motor symptoms. Often, clinicians fail to diagnosis psychosis in patients with PD and, when it is recognized, treat it suboptimally, despite the availability of multiple interventions. In this paper, we provide a summary of the current guidelines and clinical evidence for treating PDP with antipsychotics. We also provide recommendations for diagnosis and follow-up. Finally, an updated treatment algorithm for PDP that incorporates the use of pimavanserin, the only US FDA-approved drug for the treatment of PDP, was developed by extrapolating from a limited evidence base to bridge to clinical practice using expert opinion and experience. Because pimavanserin is only approved for the treatment of PDP in the US, in other parts of the world other recommendations and algorithms must be considered.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: